Skip to content
Review Open access

CD4+ cytotoxic T cells: context-dependent effectors in health and disease

Sep 2026 · Cellular & Molecular Biology Letters · 0 citations

TL;DR

This review highlights recent advances in understanding the development, regulation, and effector functions of CD4 + CTLs, while also addressing the limitations and challenges in targeting them therapeutically.

Abstract

Cytotoxic CD4 + T cells (CD4 + CTLs) have been identified as a specialized effector population characterized by potent cytotoxic machinery, including granzymes, perforin, and the Fas/FasL pathway, that enables the direct killing of MHC-II-expressing target cells. In addition to their classical helper function, CD4 + CTLs exhibit remarkable functional plasticity, which is dynamically influenced by a multilayered regulatory network integrating intrinsic transcriptional programs, extrinsic immune checkpoints, and tissue-specific microenvironmental signals. This context-dependent behavior makes CD4 + CTLs a double-edged sword in human health and disease. CD4 + CTLs are involved in protective immunity against viruses, tumors, and in eliminating senescent cells .However, they can also contribute to immunopathology in conditions such as autoimmune diseases, fibrotic disorders, atherosclerosis, and allograft rejection. Although advances in single-cell technologies have revealed the heterogeneity and TCR repertoire features, applying this knowledge to develop safe and effective therapies continues to be a significant challenge. Major obstacles include inherent plasticity, phenotypic instability, risk of off-target effects, and discrepancies between preclinical models and human diseases. This review highlights recent advances in understanding the development, regulation, and effector functions of CD4 + CTLs, while also addressing the limitations and challenges in targeting them therapeutically. Ultimately, this perspective positions CD4 + CTLs as both targets for intervention and tools for immunotherapy.

Read PDF

Similar papers

Open access Sep 2026

IL-27 induces a cytotoxic state in CD4+ T cells distinct from the Th1 lineage

CD4+ cytotoxic T lymphocytes (CD4-CTLs) are understudied immune mediators with ambiguous origins. Despite expressing RUNX3, granzyme B (GZMB), and perforin (PRF1), CD4-CTLs are frequently classified as Th1 extensions due to shared interferon-γ (IFNγ) and T-BET expression. Here, we identify interleukin-27 (IL-27) as a i...

M. Matias, R. Marrocco, Kyle Magro et al. · 0 citations
Review Open access Sep 2026

CD8+ T Cell Exhaustion and Tumor Immune Checkpoint Blockade: Mechanisms, Heterogeneity, and Combination Intervention Strategies

CD8+ T cells are the core effector cells in anti-tumor immunity, but under continuous tumor antigen stimulation and inhibitory microenvironment, they gradually enter a state of dysfunction, showing reduced effector secretion, decreased proliferation, persistent expression of inhibitory receptors, and abnormal metabolic...

Gang Liu · 0 citations
Review Nov 2026

T cell exhaustion in cancer.

Yin Min Thu, Yosuke Togashi · 1 citation
Review Open access Oct 2026

From Dysfunction to Differentiation: A New Paradigm of T Cell Exhaustion

CD8+ T cell exhaustion is the loss of certain functions typical of cytotoxic lymphocytes. CD8+ cytotoxic T cells originate from naive CD8+ T cells upon antigen exposure. Chronic or excessive antigen exposure during certain infections and cancers triggers inhibitory mechanisms that lead to functional exhaustion - a loss...

V. Stepanova, A. S. Logvinov, E. A. Emelyanov et al. · 0 citations
Open access Oct 2026

HDAC5 tunes effector competence in differentiated human CD8+ T cells through an ACTL6A–IRF4 axis

Effective therapeutics for T cell-mediated autoimmune diseases must be capable of restraining pathogenic responses in both tissue-resident effector cells and circulating memory T cells while simultaneously preserving protective immunity. However, how these distinct, differentiated T cell populations calibrate their res...

Megan E. Borregard, Yan-Dong Zhang, Yi-Zhen Jin et al. · 0 citations
Review Open access Nov 2026

T-cell immunity in anti-tumor battle.

The clinical success of T-cell-based immunotherapies has transformed oncology, yet tumor immune evasion remains a formidable barrier. In this review, we delineate the developmental and molecular landscapes that shape antitumor T-cell immunity. Following a brief overview of CD4+ helper T-cell contributions, we focus pri...

Ying Qin, Ke-Peng Yan, Dong-Yang Li et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.